• OPEN AN ACCOUNT
A+| A| A-|
Indian Indices
Sensex
73,319.55 185.23
( 0.25%)
Global Indices
Nasdaq
46,526.80 -59.95
(-0.13%)
Dow Jones
6,603.92 7.60
(0.12%)
Hang Seng
52,384.74 -1,354.94
(-2.52%)
Nikkei 225
10,436.29 71.50
(0.69%)
Forex
USD-INR
93.85 -0.46
(-0.49%)
EUR-INR
107.97 -0.33
(-0.30%)
GBP-INR
124.03 -0.65
(-0.52%)
JPY-INR
0.59 0.00
(-0.26%)

EQUITY - MARKET SCREENER

Vruddhi Engineering Works Ltd
Industry :  Trading
BSE Code
ISIN Demat
Book Value()
544157
INE0OMZ01013
33.5062514
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
N.A
33.31
49.59
EPS(TTM)
Face Value()
Div & Yield %
5.9
10
0
 

mrf ltd
Dr Reddy’s Swiss subsidiary gets USFDA CRL for biosimilar AVT03
Jan 01,2026
AVT03 is a proposed biosimilar to Amgen’s Prolia and Xgeva and has been developed by Alvotech hf. According to the company, the CRL pertains to observations made by the US Food and Drug Administration (USFDA) during a pre-licence inspection of Alvotech’s manufacturing facility in Reykjavik, Iceland.

Hyderabad-based Dr. Reddy’s Laboratories is a global pharmaceutical company. It offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC.

The company’s consolidated net profit jumped 7.3% to Rs 1,347.10 crore on a 9.8% increase in revenue from operations to Rs 8,804.90 crore in Q2 FY26 over Q2 FY25.

The counter slipped 1.66% to Rs 1,250 on the BSE.